Quantitative structure-activity relationships of antianginal drugs.

Quantitative structure-activity relationships (QSARs) of various classes of antianginal drugs, e.g. nitrates, beta-adrenergic blocking agents (beta-blockers), and calcium channel blockers (calcium antagonists), have been reviewed. This review gives an overall picture of the mode of action of each class of drugs and points out the specific physicochemical and structural properties that govern their activity. It is observed that in almost all kinds of antianginal drugs the lipophilic factor plays an important role and the next important factor seems to be the steric ones. The electronic factors are found to be occasionally important. In the case of beta-blockers, the most common factor that appeared to govern the activity remained the lipophilicity. In nitrates, too, the activity is observed to primarily depend upon the lipophilicity. In calcium channel blockers, however, the dominant effect is seen to be of steric factors. The steric roles may be essential in drug-receptor interactions, which seem to involve both hydrophobic, and to a lesser extent, electronic interactions.

[1]  J. Parratt,et al.  The effect of adrenaline, noradrenaline, and propranolol on myocardial blood flow and metabolic heat production in monkeys and baboons. , 1969, Cardiovascular research.

[2]  D. Langs,et al.  Ca2+ channel ligands: Structure‐function relationships of the 1,4‐dihydropyridines , 1989, Medicinal research reviews.

[3]  A. Martinelli,et al.  Molecular orbital studies on the mechanism of drug-receptor interaction. 2. beta-Adrenergic drugs. An approach to explain the role of the aromatic moiety. , 1977, Journal of medicinal chemistry.

[4]  L. H. Smith,et al.  Beta-adrenergic blocking agents. 10. (3-amino-2-hydroxypropoxy)anilides. , 1971, Journal of medicinal chemistry.

[5]  C. Hansch,et al.  Comparative Quantitative Structure−Activity Relationship Studies on Anti-HIV Drugs , 1999 .

[6]  M. Botta,et al.  Pyrrolo[2,1-c][1,4]benzothiazines: synthesis, structure-activity relationships, molecular modeling studies, and cardiovascular activity. , 1995, Journal of medicinal chemistry.

[7]  G. Gromo,et al.  New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones. , 1995, Journal of medicinal chemistry.

[8]  J. Tomasi,et al.  Molecular orbital studies on the mechanism of drug-receptor interaction. 1. Adrenergic drugs. Conformation and reactivity of isoproterenol and 1-(p-nitrophenyl)-2-isopropylaminoethanol. , 1974, Journal of medicinal chemistry.

[9]  D. Attwood,et al.  The surface activity and self‐association of some β‐adrenoceptor blocking agents in aqueous solution , 1979, The Journal of pharmacy and pharmacology.

[10]  M. Newman Some Observations Concerning Steric Factors , 1950 .

[11]  P. Needleman,et al.  Relationship between glutathione-dependent dentration and the vasodilator effectiveness of organic nitrates. , 1969, The Journal of pharmacology and experimental therapeutics.

[12]  M. Wasserman,et al.  Selective beta adrenergic receptor blockade in the rat. , 1972, The Journal of pharmacology and experimental therapeutics.

[13]  Satya P. Gupta,et al.  QSAR studies on hallucinogens , 1983 .

[14]  A M Triggle,et al.  1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. , 1988, Journal of medicinal chemistry.

[15]  S. Gupta Quantitative structure-activity relationships of cardiotonic agents. , 2000, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[16]  S. Gupta QSAR studies on enzyme inhibitors , 1987 .

[17]  M. Botta,et al.  Diltiazem-like calcium entry blockers: a hypothesis of the receptor-binding site based on a comparative molecular field analysis model. , 1997, Journal of medicinal chemistry.

[18]  G. M. Smith,et al.  Diethyl 3,6-dihydro-2,4-dimethyl-2,6-methano-1,3-benzothiazocine-5,11- dicarboxylates as calcium entry antagonists: new conformationally restrained analogues of Hantzsch 1,4-dihydropyridines related to nitrendipine as probes for receptor-site conformation. , 1987, Journal of medicinal chemistry.

[19]  C. Wermuth,et al.  Synthesis and beta-adrenergic blocking activity of a novel class of aromatic oxime ethers. , 1977, Journal of medicinal chemistry.

[20]  D. Triggle,et al.  High affinity binding of a calcium channel antagonist to smooth and cardiac muscle. , 1982, Biochemical and biophysical research communications.

[21]  A. M. Lands,et al.  Differentiation of receptors responsive to isoproterenol. , 1967, Life sciences.

[22]  S. P. Gupta,et al.  QSAR studies on drugs acting at the central nervous system , 1989 .

[23]  S. P. Gupta,et al.  QSAR (quantitative structure-activity relationship) studies on local anesthetics , 1991 .

[24]  A. Fleckenstein Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. , 1977, Annual review of pharmacology and toxicology.

[25]  S. Gupta Quantitative structure-activity relationships of antihypertensive agents. , 1999, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[26]  C. Romming,et al.  Crystal structures and pharmacological activity of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-(unsubstituted, 2-methyl-, 4-methyl-, 3-nitro-, 4-nitro-, and 2,4-dinitrophenyl)-1,4-dihydropyridine. , 1982, Journal of medicinal chemistry.

[27]  S. Moreland,et al.  Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers. , 1988, Journal of medicinal chemistry.

[28]  Rongan Zhang,et al.  Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators. , 1995, Journal of medicinal chemistry.

[29]  S. Unger Consequences of the Hansch Paradigm for the Pharmaceutical Industry , 1980 .

[30]  C. Hansch,et al.  An analysis of the structure-activity relationship in the adrenergic blocking activity of the beta-haloalkylamines. , 1968, Biochemical pharmacology.

[31]  S. Spergel,et al.  1-Benzazepin-2-one calcium channel blockers--VI. Receptor-binding model and possible relationship to desmethoxyverapamil. , 1993, Bioorganic & medicinal chemistry.

[32]  J. B. Farmer,et al.  Differentiation of β‐adrenoreceptors by the use of blocking agents , 1970 .

[33]  J. V. Levy Myocardial and local anesthetic actions of beta-adrenergic receptor blocking drugs: relationship to physicochemical properties. , 1968, European journal of pharmacology.

[34]  A. Verloop,et al.  Development and Application of New Steric Substituent Parameters in Drug Design , 1976 .

[35]  P. Needleman,et al.  Mechanism of tolerance development to organic nitrates. , 1973, The Journal of pharmacology and experimental therapeutics.

[36]  J. V. Levy Surface tension effects of β‐adrenergic blocking drugs , 1968 .

[37]  Stefan H. Unger,et al.  Model building in structure-activity relations. Reexamination of adrenergic blocking activity of .beta.-halo-.beta.-arylalkylamines , 1973 .

[38]  J D GRAHAM,et al.  STRUCTURE-ACTION RELATIONS IN N,N-DIMETHYL-2-HALO-GENOPHENETHYLAMINES. , 1963, Journal of medicinal chemistry.

[39]  Y. Takahata,et al.  Quantitative Structure-Activity Relationships for 1,4-Dihydropyridine Calcium Channel Antagonists (Nifedipine Analogues): A Quantum ChemicalKlassical Approach , 1994 .

[40]  Triggle Dj Calcium-channel antagonists: mechanisms of action, vascular selectivities, and clinical relevance. , 1992, Cleveland Clinic journal of medicine.

[41]  R. Loutzenhiser,et al.  Mechanisms of calcium antagonist-induced vasodilation. , 1983, Annual review of pharmacology and toxicology.

[42]  A M Triggle,et al.  Crystal structures of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-[2-nitro-, 3-cyano-, 4-(dimethylamino)-, and 2,3,4,5,6-pentafluorophenyl]-1,4-dihydropyridine. , 1980, Journal of medicinal chemistry.

[43]  A. M. Triggle,et al.  Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea-pig ileal smooth muscle. , 1983, The Journal of pharmacology and experimental therapeutics.

[44]  Svante Wold,et al.  Comparison Between X-Ray Crystallographic Data and Physicochemical Parameters with Respect to Their Information about the Calcium Channel Antagonist Activity of 4-Phenyl-1,4-dihydropyridines , 1986 .

[45]  H. Grobecker,et al.  Prediction of the non-specific cardiodepressant effects of beta-adrenoceptor blocking agents in vitro and in vivo by means of the Hansch analysis. , 1974, European journal of pharmacology.

[46]  J. Parratt,et al.  The effect of catecholamine infusions on myocardial blood flow, metabolic heat production and on general haemodynamics, before and after alprenolol (H56/28), in anaesthetized cats , 1970, British journal of pharmacology.

[47]  D. J. Triggle,et al.  New developments in calcium ion channel antagonists , 1983 .

[48]  J. Pickett,et al.  Gels in soap stabilized emulsions , 1976, The Journal of pharmacy and pharmacology.

[49]  A Hedberg,et al.  Active conformation of 1,4-dihydropyridine calcium entry blockers. Effect of size of 2-aryl substituent on rotameric equilibria and receptor binding. , 1991, Journal of medicinal chemistry.

[50]  S. Goldmann,et al.  1,4‐Dihydropyridines: Effects of Chirality and Conformation on the Calcium Antagonist and Calcium Agonist Activities , 1991 .

[51]  S. Gupta Quantitative Structure-Activity Relationship Studies on Anticancer Drugs , 1994 .

[52]  Hans-Dieter Höltje,et al.  A molecular graphics study on structure-action relationships of calcium-antagonistic and agonistic 1,4-dihydropyridines , 1987, J. Comput. Aided Mol. Des..

[53]  H. A. Germer A molecular orbital study of tissue selectivity in ß‐adrenoceptor blocking agents , 1974, The Journal of pharmacy and pharmacology.

[54]  M. Bristow,et al.  Analysis of beta receptor drug interactions in isolated rabbit atrium, aorta, stomach and trachea. , 1970, The Journal of pharmacology and experimental therapeutics.

[55]  A. M. Lands,et al.  Differentiation of Receptor Systems activated by Sympathomimetic Amines , 1967, Nature.

[56]  W G Richards,et al.  QSAR of binding of dihydropyridine‐type calcium antagonists to their receptor on ileal smooth muscle preparations , 1986, The Journal of pharmacy and pharmacology.

[57]  S. Snyder,et al.  Calcium antagonists receptor sites labeled with [3H]nitrendipine , 1982 .

[58]  A. Cammarata,et al.  Interrelationship of the regression models used for structure-activity analyses. , 1972, Journal of medicinal chemistry.